Want to see GB:CRW full AI Analyst Report?
Top Page
Craneware
(LSE:CRW)
Select Model
Select Model
Rating:63Neutral
Price Target:
1,293.00 p
▼(-42.02% Downside)
Action:Reiterated
Date:05/15/26
The score is primarily supported by strong financial quality (high gross margins and low leverage), but is held back by weak technical positioning (price below major moving averages) and only moderate valuation support (P/E 22.6 with a ~2.43% dividend yield).
Positive Factors
High gross margins
Persistently >85% gross margins indicate a scalable, software-heavy business with strong unit economics. This margin buffer supports reinvestment in product, sales and compliance, and provides resilience to price pressure or customer churn over the next several quarters.
Negative Factors
Declining free cash flow growth
A 13.4% decline in free cash flow growth signals weakening cash generation versus prior periods. If persistent it can constrain dividend capacity, capex for product development, or acquisition firepower, reducing strategic optionality across the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Persistently >85% gross margins indicate a scalable, software-heavy business with strong unit economics. This margin buffer supports reinvestment in product, sales and compliance, and provides resilience to price pressure or customer churn over the next several quarters.
Read all positive factors
Craneware (CRW) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£419.40M
Dividend Yield1.66%
Average Volume (3M)71.71K
Price to Earnings (P/E)25.9
Beta (1Y)0.65
Revenue Growth3.46%
EPS Growth46.25%
CountryUK
Employees765
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.63
Shares Outstanding34,237,150
10 Day Avg. Volume64,377
30 Day Avg. Volume71,707
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)3.07
Price to Sales (P/S)5.04
P/FCF Ratio17.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£2,600.00Price Target Upside16.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.21
Revenue Forecast (FY)£222.62M
Craneware Business Overview & Revenue Model
Company Description
Craneware plc, with its associated entities, is dedicated to creating, distributing, and maintaining cutting-edge software applications tailored for the U.S. healthcare industry. Its extensive suite of products is designed to streamline and improv...
How the Company Makes Money
Craneware makes money primarily by licensing and providing access to its healthcare software solutions and by delivering associated services that support implementation, optimization, and ongoing customer use.
Key revenue streams typically includ...
Craneware Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 211.84M | 205.66M | 189.27M | 174.02M | 165.54M | 75.58M |
| Gross Profit | 165.28M | 179.27M | 162.20M | 148.44M | 142.37M | 70.20M |
| EBITDA | 47.60M | 38.80M | 54.26M | 51.60M | 47.54M | 18.48M |
| Net Income | 22.52M | 19.66M | 11.70M | 9.23M | 9.41M | 12.90M |
Balance Sheet | ||||||
| Total Assets | 525.76M | 551.06M | 543.65M | 576.98M | 568.79M | 311.60M |
| Cash, Cash Equivalents and Short-Term Investments | 40.96M | 55.92M | 34.59M | 78.54M | 47.16M | 235.62M |
| Total Debt | 26.91M | 31.65M | 40.15M | 86.69M | 115.52M | 2.20M |
| Total Liabilities | 186.25M | 213.50M | 215.06M | 249.13M | 235.77M | 51.32M |
| Stockholders Equity | 339.51M | 337.56M | 328.59M | 327.84M | 333.02M | 260.28M |
Cash Flow | ||||||
| Free Cash Flow | 9.69M | 59.41M | 24.91M | 83.20M | 12.93M | 13.21M |
| Operating Cash Flow | 10.10M | 59.90M | 41.86M | 98.75M | 26.96M | 23.54M |
| Investing Cash Flow | -15.94M | -13.98M | -15.81M | -15.34M | -307.32M | -10.32M |
| Financing Cash Flow | -25.44M | -24.58M | -70.00M | -53.28M | 91.90M | 174.55M |
Craneware Technical Analysis
Negative
2230.00
Price Trends
1383.12
Negative
1413.15
Negative
1682.79
Negative
Market Momentum
-62.49
Negative
42.86
Neutral
86.44
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CRW, the sentiment is Negative. The current price of 2230 is above the 20-day moving average (MA) of 1258.00, above the 50-day MA of 1383.12, and above the 200-day MA of 1682.79, indicating a bearish trend. The MACD of -62.49 indicates Negative momentum. The RSI at 42.86 is Neutral, neither overbought nor oversold. The STOCH value of 86.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CRW.
Craneware Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | £57.31M | 20.95 | 8.84% | ― | -5.18% | -66.95% | |
63 Neutral | £419.40M | 25.91 | 6.65% | 1.66% | 3.46% | 46.25% | |
61 Neutral | £18.07M | -4.34 | -15.57% | ― | 13.04% | 15.88% | |
59 Neutral | £113.71M | 1,227.27 | -3.95% | ― | 19.53% | ― | |
53 Neutral | £211.02M | 48.99 | 2.09% | ― | 8.46% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | £17.00M | -8.36 | -58.72% | ― | -9.11% | 18.91% |
* Healthcare Sector Average
GB:CRW
Craneware
1,214.00
-1,150.11
-48.65%
GB:COG
Cambridge Cognition Holdings
32.00
-0.50
-1.54%
GB:IXI
IXICO plc
8.50
-2.20
-20.56%
GB:KOO
Kooth
158.00
-31.00
-16.40%
GB:DXRX
Diaceutics
135.00
8.00
6.30%
GB:OPT
Optima Health PLC
195.00
-7.96
-3.92%
Craneware Corporate Events
Other
Craneware CEO Boosts Stake Through Pension Share Purchase
Positive
Jul 6, 2026
Craneware plc reported that the pension scheme of chief executive Keith Neilson purchased 9,074 ordinary shares at 1,102 pence each on 6 July 2026. Following this transaction, Neilson’s total holding stands at 3,223,545 shares, representing ...
Business Operations and Strategy
Craneware Chair Boosts Stake in Healthcare Finance Specialist
Positive
Jul 3, 2026
Craneware plc, a specialist in healthcare financial performance and operational transformation solutions, leverages its Trisus cloud ecosystem to unify data, revenue intelligence and margin analytics for healthcare providers. Its technology suite,...
Business Operations and StrategyFinancial Disclosures
Craneware Flags FY26 Miss as 340B Slowdown Delays Growth
Negative
Jul 3, 2026
Craneware warned that its financial performance for the year to 30 June 2026 will fall short of market expectations, with revenue forecast at US$205–208 million and adjusted EBITDA at US$65–67 million, broadly flat on the prior year. T...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Craneware completes $25m share buyback and updates capital structure
Positive
May 13, 2026
Craneware has completed a $25m share buyback programme initiated in March 2026, repurchasing a total of 1,276,957 ordinary shares, including 43,134 shares bought on 12 May at a volume-weighted average price of 1,501.21p. All repurchased shares are...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Craneware Completes $25m Share Buyback, Sets New Voting Rights
Positive
May 13, 2026
Craneware has completed a $25m share buyback programme initiated in March 2026, repurchasing a total of 1,276,957 ordinary shares that will be held in treasury to cover existing employee share options and long-term incentive plan awards. The final...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Craneware Tightens Free Float with Latest Share Buyback Tranche
Positive
May 12, 2026
Craneware plc, a specialist in healthcare financial performance software, has continued its previously announced share buyback programme by purchasing 193,334 ordinary shares on the London Stock Exchange between 5 and 11 May 2026, at a volume-weig...
Business Operations and StrategyExecutive/Board Changes
Craneware Grants Modest SAYE Share Options to Senior Executives
Positive
May 5, 2026
Craneware has granted share options to three executive directors under its HMRC-approved 2018 Save As You Earn option scheme, aligning them with the same terms offered to UK employees. CEO Keith Neilson and CFO Craig Preston each received options ...
Stock BuybackRegulatory Filings and Compliance
Craneware Tightens Share Base With Treasury Buyback
Positive
May 5, 2026
Craneware plc has repurchased a total of 56,550 of its own ordinary shares between 30 April and 1 May 2026 under its previously announced share buyback programme, executing the transactions via Investec Bank at volume-weighted average prices aroun...
Stock BuybackRegulatory Filings and Compliance
Craneware Updates Market on Share Buyback and Voting Rights
Positive
May 1, 2026
Craneware has continued to execute its share buyback programme, repurchasing tranches of ordinary shares between 23 and 29 April 2026 on AIMX and the London Stock Exchange at volume‑weighted average prices around 1,530–1,570 pence. The...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Craneware Tightens Free Float with Further Share Buybacks
Positive
Apr 23, 2026
Craneware has repurchased 117,395 of its own ordinary shares on the London Stock Exchange between 17 and 22 April 2026 at prices ranging from 1,486p to 1,542p, with a volume‑weighted average price of 1,512.18p. The shares, bought through Ber...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.